Fax: (604) 875-4497
Prognostic significance of RUNX3 expression in human melanoma†
Article first published online: 23 DEC 2010
Copyright © 2010 American Cancer Society
Volume 117, Issue 12, pages 2719–2727, 15 June 2011
How to Cite
Zhang, Z., Chen, G., Cheng, Y., Martinka, M. and Li, G. (2011), Prognostic significance of RUNX3 expression in human melanoma. Cancer, 117: 2719–2727. doi: 10.1002/cncr.25838
Zhizhong Zhang's current address: Department of Molecular and Genetic Toxicology, School of Public Health, Cancer Center of Nanjing Medical University, Nanjing, China.
- Issue published online: 7 JUN 2011
- Article first published online: 23 DEC 2010
- Manuscript Accepted: 26 OCT 2010
- Manuscript Revised: 25 OCT 2010
- Manuscript Received: 14 SEP 2010
- tissue microarray
RUNX3 is a tumor suppressor that plays important roles in cell proliferation, apoptosis, and metastasis. The authors investigated the role of RUNX3 in melanoma pathogenesis and analyzed the prognostic impact of RUNX3 expression in a large series of melanoma patients.
Two sets of tissue microarrays were constructed, including 440 cases of melanomas (202 for the training set and 238 for the validation set) and 88 cases of nevi (25 normal nevi and 63 dysplastic nevi). RUNX3 expression was evaluated by immunohistochemistry.
Positive RUNX3 expression was observed in 56%, 54%, 33%, and 24% of the biopsies in normal nevi, dysplastic nevi, primary melanoma, and melanoma metastases, respectively. Significant differences for positive nuclear RUNX3 staining were observed between dysplastic nevi and primary melanomas (P = .002, chi-square test), between dysplastic nevi and melanoma metastases (P < .001, chi-square test), and between primary melanoma and melanoma metastases (P = .045, chi-square test). Loss of RUNX3 expression was correlated with a worse 5-year survival of melanoma patients in both training and validation sets. Furthermore, loss of RUNX3 expression was also correlated with a poor 5-year disease-specific survival in primary melanoma (P = .001) and metastatic melanoma patients (P = .008). Multivariate Cox regression analysis revealed that positive RUNX3 expression is an independent prognostic factor to predict melanoma patient outcome.
Our findings indicate that RUNX3 plays an important role in melanoma pathogenesis and may serve as a promising prognostic marker for melanoma. Cancer 2011;. © 2010 American Cancer Society.